Transmural care for glioma patients and their family caregivers: utility and feasibility as perceived by professional caregivers

Ine Decadt, Paul M. Clément(Universitair Ziekenhuis Leuven), C. Vrebos, Annemarie Coolbrandt(KU Leuven)

European Journal of Cancer

February 1, 2017

10.1016/s0959-8049(17)30507-5

Cited by 0

Related Papers

Lomustine and Bevacizumab in Progressive Glioblastoma

|New England Journal of Medicine|2017|994

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

|Journal of Clinical Oncology|2009|573

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

|The Lancet Oncology|2016|504

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

|Journal of Clinical Oncology|2010|445

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

|The Lancet|2017|401